Table 1: Overall cohort and comparison of groups without vs. with deterioration in EF.

- Overall No Deterioration
Deterioration p-value
n=59 n=41 n=16 -
Demographic & Co-morbidities
Age at diagnosis (years), mean (SD) 29.5 (6.8) 29.7 (7.5) 28.8 (4.5) 0.659
Black, n (%) 17 (28.8) 13 (31.7) 4 (25.0) 0.619
Hypertension, n (%) 21 (35.6) 19 (44.2) 2 (12.5) 0.024
Preeclampsia, n (%) 13 (22.0) 10(23.3) 3 (18.8) 0.710
Diabetes, n (%) 11 (18.6) 10 (23.3) 1 (6.3) 0.136
Thyroid disease, n (%) 5 (8.5) 3 (7.0) 2 (12.5) 0.498
Autoimmune disorders, n (%) 3 (5.1) 1 (2.3) 2 (12.5) 0.114
Follow-up (months), mean (SD) 76.0 (7.8) 73.0 (8.8) 84.1 (16.5) 0.530
Medications
ACEi/ARB, n (%) 53 (89.8) 38 (88.4) 15 (93.8) 0.543
Beta-blocker, n (%) 53 (89.8) 38 (88.4) 15 (93.8) 0.543
Spironolactone, n (%) 41 (69.5) 32 (74.4) 9 (56.3) 0.178
Digoxin, n (%) 33 (55.9) 24 (55.8) 9 (56.3) 0.976
Diuretic, n (%) 54 (91.5) 38 (88.4) 16 (100) 0.915
Bromocriptine, n (%) 2 (3.4) 2 (4.6) 0 (0) 0.380
Ejection Fraction
EF at diagnosis, mean (SD) 20.8 (11.0) 20.7 (10.2) 21.1 (13.0) 0.904
EF at 12 months, mean (SD) 38.8 (23.0) 40.4 (23.3) 28.8 (20.5) 0.284
Final EF, mean (SD) 37.7 (21.9) 41.6 (22.1) 25.2 (18.0) 0.010
Peak EF, mean (SD) 44.1 (20.2) 43.1 (22.3) 44.3 (16.3) 0.853
Recovered EF ≥55%, n (%) 22 (37.3) 20 (46.5) 2 (12.5) 0.016
Major Adverse Outcomes
Deceased, n (%) 12 (20.3) 6 (14.0) 6 (37.5) 0.046
Left ventricular assist device, n (%) 10 (17.2) 5 (11.6) 5 (33.3) 0.055
Cardiac Transplantation, n (%) 5 (8.8) 2 (4.8) 3 (20.0) 0.073
Inotrope-dependent, n (%) 9 (15.5) 5 (11.9) 4 (25.0) 0.218
Overall MACE, n (%) 19 (32.2) 10 (23.3) 9 (56.3) 0.016

Abbreviations: ACEi = Angiotensin-Converting Enzyme Inhibitors; ARB = Angiotensin Receptor Blocker; MACE = Major Adverse Cardiac Events (including death, left ventricular assist device, cardiac transplantation, or inotrope-dependence); EF = Ejection Fraction; SD = Standard Deviation